OncoCell aims to enter the cancer prognostic space with its noninvasive immuno-genomics RNA transcriptomics prognostic platform to help differentiate patients with aggressive forms of prostate cancer from patients with indolent disease.
Designed for small and medium-sized labs, the system offers automated blood typing and screening based on gel card technology with minimum user intervention.
CEO Yoel Ezra said the firm plans to deploy a prototype in pilot studies next year, and is eyeing opportunities in the US, Europe, India, and the Middle East.
The Erytra Eflexis is a fully automated benchtop analyzer for pretransfusion compatibility testing that facilitates multiple lab configurations and features real random access.
Factors that may have led to the explosion in testing include more consultations between patients and general practitioners, and a fear among GPs of being sued.
The instrument is a centrifuge/reader combo that automatically reads and transfers blood type and antibody screening results to patient data management software.
